Table 18Clinical evidence summary: People with type 2 diabetes vs without type 2 diabetes

OutcomesNo of Participants (studies) Follow upQuality of the evidence (GRADE)IRR2 (95% CI) [fully adjusted]Anticipated absolute effects
Risk with ControlRisk difference with patients with type 2 diabetes (95% CI)
risk of OSAN= 360,250 exposed and 1,296,489 unexposed patient cohorts1

VERY LOW3

due to risk of bias

1.36 (1.30-1.42)5

Type 2 diabetes: 3110/360250 (0.88%)

Without type 2 diabetes: 1296489/5968 (0.46%)

-Not estimable4
1

Methods: multivariable analysis. Key covariates included: age, sex, BMI, Townsend deprivation quintile, smoking status and ethnicity.

2

adjusted incidence rate ratio

3

Risk of bias was assessed using the QUIPS checklist. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias; no indirectness

4

Data as reported as in the paper

5

Default MID (0.5XSD) used to assess imprecision. Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. GC considered the clinical importance of the effect estimate for each analysis on a case by case basis, taking into consideration the increment of the risk factor and the outcome under study.

From: When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome

Cover of When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome
When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome: Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s: Evidence review A.
NICE Guideline, No. 202.
National Guideline Centre (UK).
Copyright © NICE 2021.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.